Biology & Medicine News and Discussions

weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

Mucus-based lubricant proves highly effective against HIV and herpes
https://medicalxpress.com/news/2022-09- ... e-hiv.html
by KTH Royal Institute of Technologyquote]

Cow mucus provides the basis for a synthetic prophylactic gel developed at KTH Royal Institute of Technology to protect against HIV and herpes transmission. The lubricating gel proved 70% effective in lab tests against HIV, and 80% effective against herpes.

The viral prophylactic tests were conducted in a lab on several types of cells. The results were reported today in the Advanced Science.

Hongji Yan, a biomaterials researcher at KTH, says the promising results raise hope that when it becomes available as a product, the gel could help reverse troubling trends in the spread of sexually transmitted infections.

More than 1 million STIs are acquired every day worldwide and most of these are asymptomatic, according to the World Health Organization (WHO). AIDS, the disease caused by HIV, remains a significant global epidemic, and adolescent girls and young women are twice as likely as men to contract HIV as their male counterparts according to UNAIDS.

The lubricant is derived from mucin, a main component of mucus that is produced in the human body, though suppliers provide the bovine type in purified form for fabrication of hydrogels.[/quote]
weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

New drug therapy for young children with severe eczema
https://medicalxpress.com/news/2022-09- ... evere.html
by University of Manchester
A biologic therapy for very young children with a moderate to severe form of a common skin condition has been shown to be safe and effective in an international trial which involved University of Manchester clinical scientists working within the Clinical Trials Facility at Royal Manchester Children's Hospital.

Sponsored by the Biotech companies Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomized double-blind trial of a monoclonal antibody for any skin disease in patients aged six months to six years.

The study, published in The Lancet showed that the drug greatly improved the severity of the condition, reducing skin itch and pain within two weeks.

It also significantly improved patients' sleep, and the quality of life of patients and their parents.
User avatar
caltrek
Posts: 6509
Joined: Mon May 17, 2021 1:17 pm

Re: Biology & Medicine News and Discussions

Post by caltrek »

Experimental Treatment Puts 5 Cases of Lupus Into Remission
September 16, 2022

Introduction:
(IFL Science) In a result that some immunologists are calling “revolutionary,” five cases of the severe autoimmune disease lupus have been sent into remission – and it’s all thanks to an experimental therapy previously known as a cancer treatment.

“We are very excited about these results,” said Georg Schett, a professor of rheumatology at Friedrich-Alexander University in Erlangen-Nuremberg and lead researcher on the project.

“Several other autoimmune diseases which are dependent on B cells and show autoantibodies may respond to this treatment,” he told The Guardian. “These include rheumatoid arthritis, myositis and systemic sclerosis… also diseases like multiple sclerosis may be very responsive to CAR T-cell treatment.”

But what is CAR T-cell therapy? It’s a fairly new treatment, usually used in the treatment of leukemia or lymphoma, which is both incredibly specialized and complex to administer, and almost astonishingly simple in concept. It's based on the miniature arms race that occurs between invading cancer cells and our body's own immune response to them: the immune system creates and deploys T-cells, a type of white blood cell which can hunt down and kill cancer cells in the body, while the cancer cells in turn can disguise themselves and hide from the incoming defenses.

Against that background, CAR T-cell therapy is basically a way to give those T-cells a helping hand – setting up a Special Forces squad, if you like. “[It] uses a patient's own T-cells, which are genetically modified in a lab, expanded into large numbers, and then reinfused back into the patient,” explained Chris McNamara, Consultant Hematologist at HCA Healthcare UK, in an explainer article on the treatment. “These new T-cells have a chimeric antigen receptor (CAR), which can identify protein on the surface of the cancer cells and destroy them.”
Read more of the IFL Science article here: https://www.iflscience.com/-it-s-kind- ... ion-65365

Here is the article presented by the HCA Healthcare UK that explains the treatment: https://www.hcahealthcare.co.uk/blogs/u ... ll-therapy
Don't mourn, organize.

-Joe Hill
weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

Rheumatoid arthritis drug effective against myasthenia gravis
https://medicalxpress.com/news/2022-09- ... henia.html
by Karolinska Institutet

Early intervention with rituximab, a drug used in the treatment of rheumatoid arthritis (RA), can reduce the risk of deterioration in myasthenia gravis, an autoimmune disease that causes loss of muscle control. This is according to a randomized clinical study led by researchers at Karolinska Institutet in Sweden and published in the journal JAMA Neurology.

"Patients with new onset myasthenia who received rituximab as a complement to standard of care showed greater improvement compared with patients who were given a placebo," says Fredrik Piehl, professor at the Department of Clinical Neuroscience, Karolinska Institutet, and the study's principal investigator. "They also needed fewer adjuvant treatments and lower doses of cortisone than the placebo group. These are encouraging results that give hope for a more effective strategy for controlling new onset myasthenia more quickly, even if larger studies will be needed to assess the long-term effects of the treatment."

In myasthenia gravis, the immune system attacks the receptors between nerves and muscles, causing abnormal muscle weakness and fatigue. It often starts around the eye muscles but usually spread to other muscles in the body. The disease tends to progress in flare-ups and since there is no curative treatment, intervention is primarily aimed at dampening the immune system and treating the symptoms. Around 25 per 100,000 people live with the disease in Sweden, the majority of whom are women.

There is only one approved drug for myasthenia, Soliris, but the treatment is costly, which means that very few patients—none to date in Sweden—have benefited from it. Instead, many patients are treated with cortisone, which can cause side effects, and older tablet treatments that tend to lack scientific support.
weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

A smartphone's camera and flash could help people measure blood oxygen levels at home

by University of Washington
First, pause and take a deep breath.

When we breathe in, our lungs fill with oxygen, which is distributed to our red blood cells for transportation throughout our bodies. Our bodies need a lot of oxygen to function, and healthy people have at least 95% oxygen saturation all the time.

Conditions like asthma or COVID-19 make it harder for bodies to absorb oxygen from the lungs. This leads to oxygen saturation percentages that drop to 90% or below, an indication that medical attention is needed.

In a clinic, doctors monitor oxygen saturation using pulse oximeters—those clips you put over your fingertip or ear. But monitoring oxygen saturation at home multiple times a day could help patients keep an eye on COVID symptoms, for example.
https://medicalxpress.com/news/2022-09- ... xygen.html
weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

Researchers advance efforts to tailor drug delivery to cells' mitochondria
https://phys.org/news/2022-09-advance-e ... ivery.html
by Johns Hopkins University School of Medicine
In a study using lab-grown cells, Johns Hopkins Medicine researchers specializing in aging report they have successfully delivered a common blood pressure drug directly to the inner membrane of mitochondria.

Developing ways to directly target these energy-producing parts of the cell for delivery of drugs has long been a goal for researchers because mitochondria drive, control or play a role in almost every biological process, including natural cell death and aging. Alterations or declines in mitochondrial activity and pathways are closely aligned with decreased organ function and frailty. But because of the mitochondria's double-membrane structure, scientists have found it challenging to get drug molecules to penetrate the inner membrane and gain access to core functions of the organelles.

The new study, described in the Aug. 4 issue of PNAS Nexus, reports on a method that essentially hijacks a system already used by mitochondria to transport oxygen and other chemicals to the inner membrane.

"Our study shows that we can use the body's natural mitochondrial transport system to deliver drugs much more precisely," says Peter Abadir, M.D., associate professor of geriatric medicine and gerontology at the Johns Hopkins University School of Medicine.

For the study, the researchers lab-synthesized three naturally occurring transport proteins that interact with mitochondria. They then fused a commonly prescribed blood pressure medication (losartan) to each of these three proteins to determine which had the highest success rate penetrating the inner membrane of the mitochondria. These fused proteins, dubbed mtLOS1, mtLOS2 and mtLOS3, when introduced to lab-grown cells in separate trials, were able to transport the drug directly to the mitochondria at a significantly higher concentration than was possible with free losartan not fused to the transport protein. This could be seen under a microscope using florescence.
weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

Gel treats gum disease by fighting inflammation
https://medicalxpress.com/news/2022-09- ... ation.html
by New York University
A topical gel that blocks the receptor for a metabolic byproduct called succinate treats gum disease by suppressing inflammation and changing the makeup of bacteria in the mouth, according to a new study led by researchers at NYU College of Dentistry and published in Cell Reports.

The research, conducted in mice and using human cells and plaque samples, lays the groundwork for a non-invasive treatment for gum disease that people could apply to the gums at home to prevent or treat gum disease.

Gum disease (also known as periodontitis or periodontal disease) is one of the most prevalent inflammatory diseases, affecting nearly half of adults 30 and older. It is marked by three components: inflammation, an imbalance of unhealthy and healthy bacteria in the mouth, and destruction of the bones and structures that support the teeth. Uncontrolled gum disease can lead to painful and bleeding gums, difficulty chewing, and tooth loss.

"No current treatment for gum disease simultaneously reduces inflammation, limits disruption to the oral microbiome, and prevents bone loss. There is an urgent public health need for more targeted and effective treatments for this common disease," said Yuqi Guo, an associate research scientist in the Department of Molecular Pathobiology at NYU Dentistry and the study's co-first author.
weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

Epigenetic treatment in mice improves spinal cord regeneration after injury
https://medicalxpress.com/news/2022-09- ... -cord.html
by Public Library of Science

Currently, spinal cord injury does not have any effective treatments; physical rehabilitation can help patients regain some mobility, but for severe cases the outcomes are extremely limited by the failure of spinal neurons to regenerate naturally after injury. However, in a study publishing September 20th in the open access journal PLOS Biology, researchers led by Simone Di Giovanni at Imperial College London in the U.K. show that weekly treatments with an epigenetic activator can aid the regrowth of sensory and motor neurons in the spinal cord when given to mice 12 weeks after severe injury.

Building on their past success, researchers used a small molecule called TTK21 to activate genetic programming that induces axon regeneration in neurons. TTK21 changes the epigenetic state of genes by activating the CBP/p300 family of co-activator proteins. They tested TTK21 treatment in a mouse model of severe spinal cord injury. The mice lived in an enriched environment that gave them opportunities to be physically active, as is encouraged in human patients.

Treatment began 12 weeks after severe spinal cord injury and lasted for 10 weeks. Researchers found several improvements after TTK21 treatment compared with control treatment. The most noticeable effect was more axon sprouting in the spinal cord. They also found that retraction of motor axons above the point of injury halted, and that sensory axon growth increased. These changes were likely due to the observed increase in gene expression related to regeneration. The next step will be to enhance these effects even more and to trigger the regenerating axons to reconnect to the rest of the nervous system so that animals can regain their ability to move with ease.
weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

First direct evidence that babies react to taste and smell in the womb
https://medicalxpress.com/news/2022-09- ... -womb.html
by Durham University
A study led by Durham University's Fetal and Neonatal Research Lab, UK, took 4D ultrasound scans of 100 pregnant women to see how their unborn babies responded after being exposed to flavors from foods eaten by their mothers.

Researchers looked at how the fetuses reacted to either carrot or kale flavors just a short time after the flavors had been ingested by the mothers.

Fetuses exposed to carrot showed more "laughter-face" responses while those exposed to kale showed more "cry-face" responses.

Their findings could further our understanding of the development of human taste and smell receptors.

The researchers also believe that what pregnant women eat might influence babies' taste preferences after birth and potentially have implications for establishing healthy eating habits.

The study is published in the journal Psychological Science.
weatheriscool
Posts: 12946
Joined: Sun May 16, 2021 6:16 pm

Re: Biology & Medicine News and Discussions

Post by weatheriscool »

Researchers reveal new strategy to prevent blood clots without increasing the risk of bleeding
https://phys.org/news/2022-09-reveal-st ... clots.html
by University Hospitals Cleveland Medical Center
A nanoparticle therapy developed by investigators at University Hospitals (UH) and Case Western Reserve University targets overactive neutrophils, a specific kind of white blood cell, to prevent almost all types of blood clots while causing no increased risk for bleeding. The preclinical findings, published in Science Translational Medicine, may lead to safer ways to care for patients impacted by blood clots. According to the Centers for Disease Control and Prevention (CDC), roughly 900,000 people in the U.S. suffer from life-threatening blood clots each year.

"What we are showing for the first time is that neutrophils are key drivers of both arterial and venous thrombosis. And when you target a neutrophil, you do not increase bleeding risk, you only decrease clotting risk," said Lalitha Nayak, MD, study lead author, hematologist/oncologist at UH Seidman Cancer Center, member of the Developmental Therapeutics Program at Case Comprehensive Cancer Center, and associate professor at Case Western Reserve School of Medicine.
Post Reply